| Sep 15, 2026 | WILLIAM ROTE | CHIEF RESEARCH OFFICER | SELL | 17.548K | $42.12 | $9.0M |
| Sep 15, 2026 | Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | SELL | 25.000K | $39.37 | $13.8M |
| Sep 15, 2026 | Jula Inrig | EVP, HEAD R&D & CMO | SELL | 12.279K | $35.64 | $2.5M |
| Sep 15, 2026 | Elizabeth E Reed | CHIEF LEGAL OFFICER AND GC | SELL-OPTIONS | — | $38.90 | $1.8M |
| Sep 15, 2026 | Eric Dube | CHIEF EXECUTIVE OFFICER | SELL-OPTIONS | — | $43.41 | $16.1M |
| Sep 15, 2026 | Christopher Cline | CHIEF FINANCIAL OFFICER | SELL | 30.508K | $39.89 | $2.8M |
| Sep 15, 2026 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | SELL-OPTIONS | — | $43.26 | $205K |
| Sep 10, 2026 | Jeffrey Meckler | — | SELL-OPTIONS | — | $44.64 | $907K |
| Sep 2, 2026 | Christopher Cline | CHIEF FINANCIAL OFFICER | SELL | 642.000 | $66.37 | $43K |
| Aug 17, 2026 | GARY LYONS | — | SELL-OPTIONS | — | $40.36 | $458K |
| Jun 12, 2026 | Timothy Coughlin | — | SELL-OPTIONS | — | $38.30 | $236K |
| Jun 12, 2026 | Roy Baynes | — | SELL-OPTIONS | — | $35.69 | $129K |
| May 15, 2026 | Timothy Coughlin | — | SELL | 3.250K | $43.49 | $141K |
| May 5, 2026 | Roy Baynes | — | SELL-OPTIONS | — | $32.46 | $128K |
| May 4, 2026 | Jeffrey Meckler | — | SELL-OPTIONS | — | $30.66 | $229K |
| May 4, 2026 | WILLIAM ROTE | CHIEF RESEARCH OFFICER | SELL-OPTIONS | 1.487K | $43.95 | $121K |
| May 4, 2026 | Elizabeth E Reed | CHIEF LEGAL OFFICER AND GC | SELL-OPTIONS | — | $31.51 | $733K |
| May 4, 2026 | Jula Inrig | CHIEF MEDICAL OFFICER | SELL-OPTIONS | 1.765K | $33.77 | $567K |
| May 4, 2026 | Peter Heerma | CHIEF COMMERCIAL OFFICER | SELL-OPTIONS | 2.076K | $46.65 | $101K |
| May 4, 2026 | Eric Dube | CHIEF EXECUTIVE OFFICER | SELL-OPTIONS | — | $43.95 | $989K |
| May 4, 2026 | Christopher Cline | CHIEF FINANCIAL OFFICER | SELL-OPTIONS | 1.759K | $46.31 | $115K |
| May 1, 2026 | Roy Baynes | — | SELL-OPTIONS | — | $25.52 | $365K |
| Apr 22, 2026 | WILLIAM ROTE | CHIEF RESEARCH OFFICER | SELL | 9.100K | $39.09 | $356K |
| Apr 14, 2026 | GARY LYONS | — | SELL-OPTIONS | — | $28.70 | $198K |
| Apr 14, 2026 | Roy Baynes | — | SELL-OPTIONS | — | $29.44 | $776K |
| Apr 14, 2026 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | SELL | 6.727K | $28.56 | $658K |
| Apr 13, 2026 | Peter Heerma | CHIEF COMMERCIAL OFFICER | GRANT | 6.785K | $41.93 | $303K |
| Apr 13, 2026 | Eric Dube | CHIEF EXECUTIVE OFFICER | GRANT | — | $41.09 | $2.6M |
| Apr 13, 2026 | Elizabeth E Reed | CHIEF LEGAL OFFICER AND GC | SELL-OPTIONS | — | $29.52 | $1.5M |
| Apr 13, 2026 | Christopher Cline | CHIEF FINANCIAL OFFICER | GRANT | 5.673K | $41.91 | $349K |
| Apr 13, 2026 | Jula Inrig | CHIEF MEDICAL OFFICER | GRANT | 5.767K | $42.01 | $346K |
| Apr 6, 2026 | Roy Baynes | — | SELL-OPTIONS | — | $29.76 | $65K |
| Apr 1, 2026 | Eric Dube | CHIEF EXECUTIVE OFFICER | SELL-OPTIONS | — | $23.20 | $928K |
| Apr 1, 2026 | Elizabeth E Reed | CHIEF LEGAL OFFICER AND GC | SELL-OPTIONS | — | $22.73 | $145K |
